TITLE

Exenatide Response in an Adolescent's Morbid Obesity

AUTHOR(S)
Soriano Sánchez, Ricardo; López Ruiz, Alfonso; Núñez Sánchez, M. Ángeles; García-Talavera Espín, Noelia Victoria; Meoro Avilés, Amparo; Gallego García, María Teresa; del Peso Gilsanz, Cristina; Soriano Palao, José
PUB. DATE
April 2014
SOURCE
Pharmacology & Pharmacy;Apr2014, Vol. 5 Issue 4, p419
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Adolescent obesity is a health problem worldwide. Drug therapy for obesity in children is only acceptable if done within the framework of a comprehensive weight loss, prevention of comorbidities, including health education, changes in lifestyles, diet and exercise. These pharmacological treatments indicate that mainly young patients did not respond to standard measures and developing complications. The role of bariatric surgery, with or without the use of drugs is subject to further research to elucidate its role among the various treatment options for these patients. Currently being studied a wide range of drugs to those included gastrointestinal hormones. Scientific information regarding the use of exenatide in obese patients without diabetes is still limited. The use of exenatide in adolescents with morbid obesity may represent a therapeutic complement invaluable, effective and free of complications, and prevents future bariatric surgery.
ACCESSION #
96213943

 

Related Articles

  • Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity Pharmacotherapy. Ravussin, Eric; Smith, Steven R.; Mitchell, Julie A.; Shringarpure, Reshma; Shan, Kevin; Maier, Holly; Koda, Joy E.; Weyer, Christian // Obesity (19307381);Sep2009, Vol. 17 Issue 9, p1736 

    The neurohormonal control of body weight involves a complex interplay between long-term adiposity signals (e.g., leptin), and short-term satiation signals (e.g., amylin). In diet-induced obese (DIO) rodents, amylin/leptin combination treatment led to marked, synergistic, fat-specific weight...

  • Treating the obese teenager. Dietz, William; Rolls, Barbara J.; Stice, Eric; Yanovski, Jack A. // Patient Care;10/15/2001, Vol. 35 Issue 19, p57 

    Provides information on the treatment of obesity among teenagers. Discussion on body mass index; Medical screening suggested to assess obesity; Health risk of obesity; Evaluation of weight loss programs.

  • FDA Approval of Obesity Drugs. Morrato, Elaine H.; Allison, David B. // JAMA: Journal of the American Medical Association;9/19/2012, Vol. 308 Issue 11, p1097 

    The authors discusses about the obesity epidemic and the need of safe and effective treatments by patients and physicians. They inform that pharmaceutical companies in the U.S. are responding with significant investment in drug developments. They mention that drugs provide therapeutic options...

  • 1716 LOCUST. Nickell, Karol Dewulf // Better Homes & Gardens;Apr2004, Vol. 82 Issue 4, p10 

    Looks into the prevalence of obesity among teenagers in the U.S. Higher rate of obesity among kids in the U.S. as compared to kids in other leading industrialized countries; Potential health problems brought about by obesity; Measures needed to make kids healthy.

  • WEIGHT WATCHER. Springen, Karen // Newsweek;2/6/2006, Vol. 147 Issue 6, p70 

    This article discusses the pros and cons of taking the weight loss drug orlistat, a medication which is marketed by Roche and is sold under the name of Xenical. Orlistat is prescribed by doctors as a weight loss drug and is typically recommended only for those patients suffering from...

  • Weighing up the evidence: a meta-analysis and therapeutic audit of the treatments for obesity. Lawley, Josh // Bioscience Horizons: The National Undergraduate Research Journal;Jan2014, Vol. 7, p1 

    There is an urgent need to find the most cost-effective treatment to help manage the ‘epidemic of obesity’. This study examined the long-term efficacy of lifestyle, pharmaceutical and surgical interventions of reducing weight in obese patients by carrying out a meta-analysis of...

  • Devices hold top billing over pharma solutions for obesity. FORD, OMAR // Medical Device Daily;12/11/2008, Vol. 12 Issue 220, p1 

    The article deals with the upcoming pharmaceutical solutions for obesity discussed by a four-person panel during the 2008 Healthcare Conference of RBC Capital Markets. The panel believed that the pharmaceutical industry in the U.S. can become popular again in preventing obesity. Pharmaceutical...

  • Intragastric Balloon in Association with Lifestyle and/or Pharmacotherapy in the Long-Term Management of Obesity. Farina, Maria; Baratta, Roberto; Nigro, Angela; Vinciguerra, Federica; Puglisi, Concetta; Schembri, Roberto; Virgilio, Clara; Vigneri, Riccardo; Frittitta, Lucia // Obesity Surgery;Apr2012, Vol. 22 Issue 4, p565 

    Background: Intragastric balloon (BioEnterics Intragastric Balloon, BIB®) or pharmacotherapy are possible options for the treatment of obese patients when traditional approaches have failed. The aim of our study was to compare in obese patients the effect on weight loss and metabolic changes...

  • Recent Advances in Obesity Pharmacotherapy. Mayer, Marcos A.; Höcht, Christian; Puyó, Ana; Taira, Carlos A. // Current Clinical Pharmacology;Jan2009, Vol. 4 Issue 1, p53 

    Obesity is considered a worldwide epidemic. Weight reduction by means of lifestyle changes is difficult to achieve, and pharmacotherapy is frequently needed. Although all currently approved anti-obesity agents have proven to be effective to achieve some degree of weight reduction and improve...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics